nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—Mesalazine—PPARG—pancreatic cancer	0.00619	0.405	CrCbGaD
Methyldopa—Aminosalicylic Acid—PTGS2—pancreatic cancer	0.00333	0.218	CrCbGaD
Methyldopa—Epinephrine—TNF—pancreatic cancer	0.00317	0.207	CrCbGaD
Methyldopa—Liver function test abnormal—Docetaxel—pancreatic cancer	0.00278	0.00287	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00276	0.00285	CcSEcCtD
Methyldopa—Orthostatic hypotension—Docetaxel—pancreatic cancer	0.00275	0.00284	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.00273	0.00282	CcSEcCtD
Methyldopa—Angiopathy—Irinotecan—pancreatic cancer	0.00273	0.00282	CcSEcCtD
Methyldopa—Paraesthesia—Tamoxifen—pancreatic cancer	0.00272	0.00281	CcSEcCtD
Methyldopa—Cardiac disorder—Gemcitabine—pancreatic cancer	0.00272	0.00281	CcSEcCtD
Methyldopa—Breast disorder—Docetaxel—pancreatic cancer	0.00272	0.00281	CcSEcCtD
Methyldopa—Mediastinal disorder—Irinotecan—pancreatic cancer	0.00271	0.0028	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Docetaxel—pancreatic cancer	0.00271	0.0028	CcSEcCtD
Methyldopa—Arthralgia—Sunitinib—pancreatic cancer	0.00271	0.0028	CcSEcCtD
Methyldopa—Myalgia—Sunitinib—pancreatic cancer	0.00271	0.0028	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.00269	0.00278	CcSEcCtD
Methyldopa—Colitis—Epirubicin—pancreatic cancer	0.00268	0.00277	CcSEcCtD
Methyldopa—Angiopathy—Gemcitabine—pancreatic cancer	0.00266	0.00275	CcSEcCtD
Methyldopa—Mediastinal disorder—Gemcitabine—pancreatic cancer	0.00264	0.00273	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00262	0.00271	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—pancreatic cancer	0.00261	0.171	CrCbGaD
Methyldopa—Oedema—Sunitinib—pancreatic cancer	0.0026	0.00268	CcSEcCtD
Methyldopa—Constipation—Tamoxifen—pancreatic cancer	0.00259	0.00268	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00259	0.00268	CcSEcCtD
Methyldopa—Hepatocellular injury—Doxorubicin—pancreatic cancer	0.00259	0.00267	CcSEcCtD
Methyldopa—Flatulence—Irinotecan—pancreatic cancer	0.00258	0.00267	CcSEcCtD
Methyldopa—Infection—Sunitinib—pancreatic cancer	0.00258	0.00267	CcSEcCtD
Methyldopa—Constipation—Erlotinib—pancreatic cancer	0.00257	0.00265	CcSEcCtD
Methyldopa—Nervous system disorder—Sunitinib—pancreatic cancer	0.00255	0.00263	CcSEcCtD
Methyldopa—Thrombocytopenia—Sunitinib—pancreatic cancer	0.00254	0.00263	CcSEcCtD
Methyldopa—Angina pectoris—Docetaxel—pancreatic cancer	0.00253	0.00262	CcSEcCtD
Methyldopa—Skin disorder—Sunitinib—pancreatic cancer	0.00252	0.00261	CcSEcCtD
Methyldopa—Colitis—Doxorubicin—pancreatic cancer	0.00248	0.00257	CcSEcCtD
Methyldopa—Pancytopenia—Docetaxel—pancreatic cancer	0.00247	0.00255	CcSEcCtD
Methyldopa—Body temperature increased—Erlotinib—pancreatic cancer	0.00237	0.00245	CcSEcCtD
Methyldopa—Weight increased—Docetaxel—pancreatic cancer	0.00237	0.00245	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00237	0.00245	CcSEcCtD
Methyldopa—Leukopenia—Irinotecan—pancreatic cancer	0.00235	0.00242	CcSEcCtD
Methyldopa—Paraesthesia—Sunitinib—pancreatic cancer	0.00233	0.00241	CcSEcCtD
Methyldopa—Infestation NOS—Docetaxel—pancreatic cancer	0.00232	0.0024	CcSEcCtD
Methyldopa—Infestation—Docetaxel—pancreatic cancer	0.00232	0.0024	CcSEcCtD
Methyldopa—Leukopenia—Gemcitabine—pancreatic cancer	0.00229	0.00236	CcSEcCtD
Methyldopa—Jaundice—Docetaxel—pancreatic cancer	0.00226	0.00234	CcSEcCtD
Methyldopa—Eczema—Epirubicin—pancreatic cancer	0.00226	0.00233	CcSEcCtD
Methyldopa—Leukopenia—Fluorouracil—pancreatic cancer	0.00225	0.00232	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00224	0.00232	CcSEcCtD
Methyldopa—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.00224	0.00231	CcSEcCtD
Methyldopa—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00223	0.00231	CcSEcCtD
Methyldopa—Constipation—Sunitinib—pancreatic cancer	0.00222	0.0023	CcSEcCtD
Methyldopa—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.00219	0.00227	CcSEcCtD
Methyldopa—Asthenia—Tamoxifen—pancreatic cancer	0.00218	0.00225	CcSEcCtD
Methyldopa—Arthralgia—Gemcitabine—pancreatic cancer	0.00217	0.00225	CcSEcCtD
Methyldopa—Myalgia—Gemcitabine—pancreatic cancer	0.00217	0.00225	CcSEcCtD
Methyldopa—Agranulocytosis—Docetaxel—pancreatic cancer	0.00216	0.00224	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00216	0.00223	CcSEcCtD
Methyldopa—Asthenia—Erlotinib—pancreatic cancer	0.00215	0.00222	CcSEcCtD
Methyldopa—Oedema—Irinotecan—pancreatic cancer	0.00214	0.00221	CcSEcCtD
Methyldopa—Myalgia—Fluorouracil—pancreatic cancer	0.00214	0.00221	CcSEcCtD
Methyldopa—Infection—Irinotecan—pancreatic cancer	0.00213	0.0022	CcSEcCtD
Methyldopa—Nervous system disorder—Irinotecan—pancreatic cancer	0.0021	0.00217	CcSEcCtD
Methyldopa—Thrombocytopenia—Irinotecan—pancreatic cancer	0.00209	0.00216	CcSEcCtD
Methyldopa—Eczema—Doxorubicin—pancreatic cancer	0.00209	0.00216	CcSEcCtD
Methyldopa—Oedema—Gemcitabine—pancreatic cancer	0.00208	0.00215	CcSEcCtD
Methyldopa—Hepatitis—Docetaxel—pancreatic cancer	0.00208	0.00215	CcSEcCtD
Methyldopa—Diarrhoea—Tamoxifen—pancreatic cancer	0.00207	0.00214	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.00207	0.00214	CcSEcCtD
Methyldopa—Infection—Gemcitabine—pancreatic cancer	0.00207	0.00214	CcSEcCtD
Methyldopa—Body temperature increased—Sunitinib—pancreatic cancer	0.00205	0.00212	CcSEcCtD
Methyldopa—Diarrhoea—Erlotinib—pancreatic cancer	0.00205	0.00212	CcSEcCtD
Methyldopa—Oedema—Fluorouracil—pancreatic cancer	0.00205	0.00212	CcSEcCtD
Methyldopa—Connective tissue disorder—Docetaxel—pancreatic cancer	0.00205	0.00211	CcSEcCtD
Methyldopa—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00204	0.00211	CcSEcCtD
Methyldopa—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.00204	0.00211	CcSEcCtD
Methyldopa—Infection—Fluorouracil—pancreatic cancer	0.00204	0.0021	CcSEcCtD
Methyldopa—Skin disorder—Gemcitabine—pancreatic cancer	0.00202	0.00209	CcSEcCtD
Methyldopa—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00201	0.00208	CcSEcCtD
Methyldopa—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.00201	0.00207	CcSEcCtD
Methyldopa—Dizziness—Tamoxifen—pancreatic cancer	0.00201	0.00207	CcSEcCtD
Methyldopa—Dizziness—Erlotinib—pancreatic cancer	0.00198	0.00205	CcSEcCtD
Methyldopa—Cardiac disorder—Docetaxel—pancreatic cancer	0.00193	0.002	CcSEcCtD
Methyldopa—Vomiting—Tamoxifen—pancreatic cancer	0.00193	0.00199	CcSEcCtD
Methyldopa—Paraesthesia—Irinotecan—pancreatic cancer	0.00192	0.00199	CcSEcCtD
Methyldopa—Hypersensitivity—Sunitinib—pancreatic cancer	0.00191	0.00198	CcSEcCtD
Methyldopa—Rash—Tamoxifen—pancreatic cancer	0.00191	0.00198	CcSEcCtD
Methyldopa—Dermatitis—Tamoxifen—pancreatic cancer	0.00191	0.00197	CcSEcCtD
Methyldopa—Vomiting—Erlotinib—pancreatic cancer	0.00191	0.00197	CcSEcCtD
Methyldopa—Headache—Tamoxifen—pancreatic cancer	0.0019	0.00196	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.0019	0.00196	CcSEcCtD
Methyldopa—Rash—Erlotinib—pancreatic cancer	0.00189	0.00195	CcSEcCtD
Methyldopa—Dermatitis—Erlotinib—pancreatic cancer	0.00189	0.00195	CcSEcCtD
Methyldopa—Angiopathy—Docetaxel—pancreatic cancer	0.00189	0.00195	CcSEcCtD
Methyldopa—Headache—Erlotinib—pancreatic cancer	0.00188	0.00194	CcSEcCtD
Methyldopa—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00188	0.00194	CcSEcCtD
Methyldopa—Liver function test abnormal—Epirubicin—pancreatic cancer	0.00187	0.00194	CcSEcCtD
Methyldopa—Paraesthesia—Gemcitabine—pancreatic cancer	0.00187	0.00193	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00187	0.00193	CcSEcCtD
Methyldopa—Asthenia—Sunitinib—pancreatic cancer	0.00186	0.00193	CcSEcCtD
Methyldopa—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.00185	0.00192	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00185	0.00191	CcSEcCtD
Methyldopa—Paraesthesia—Fluorouracil—pancreatic cancer	0.00184	0.0019	CcSEcCtD
Methyldopa—Breast disorder—Epirubicin—pancreatic cancer	0.00183	0.0019	CcSEcCtD
Methyldopa—Constipation—Irinotecan—pancreatic cancer	0.00183	0.00189	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.00183	0.00189	CcSEcCtD
Methyldopa—Mental disorder—Docetaxel—pancreatic cancer	0.00182	0.00188	CcSEcCtD
Methyldopa—Nausea—Tamoxifen—pancreatic cancer	0.0018	0.00186	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.0018	0.00186	CcSEcCtD
Methyldopa—Constipation—Gemcitabine—pancreatic cancer	0.00178	0.00184	CcSEcCtD
Methyldopa—Nausea—Erlotinib—pancreatic cancer	0.00178	0.00184	CcSEcCtD
Methyldopa—Diarrhoea—Sunitinib—pancreatic cancer	0.00178	0.00184	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00177	0.00183	CcSEcCtD
Methyldopa—Abdominal distension—Epirubicin—pancreatic cancer	0.00177	0.00182	CcSEcCtD
Methyldopa—Eosinophilia—Epirubicin—pancreatic cancer	0.00174	0.00179	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.00173	0.00179	CcSEcCtD
Methyldopa—Pancreatitis—Epirubicin—pancreatic cancer	0.00172	0.00178	CcSEcCtD
Methyldopa—Dizziness—Sunitinib—pancreatic cancer	0.00172	0.00177	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.00172	0.00177	CcSEcCtD
Methyldopa—Angina pectoris—Epirubicin—pancreatic cancer	0.00171	0.00177	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—pancreatic cancer	0.0017	0.00175	CcSEcCtD
Methyldopa—Body temperature increased—Irinotecan—pancreatic cancer	0.00169	0.00175	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.00169	0.00175	CcSEcCtD
Methyldopa—Pancytopenia—Epirubicin—pancreatic cancer	0.00167	0.00172	CcSEcCtD
Methyldopa—Vomiting—Sunitinib—pancreatic cancer	0.00165	0.00171	CcSEcCtD
Methyldopa—Body temperature increased—Gemcitabine—pancreatic cancer	0.00165	0.0017	CcSEcCtD
Methyldopa—Rash—Sunitinib—pancreatic cancer	0.00164	0.00169	CcSEcCtD
Methyldopa—Dermatitis—Sunitinib—pancreatic cancer	0.00164	0.00169	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—pancreatic cancer	0.00163	0.00169	CcSEcCtD
Methyldopa—Headache—Sunitinib—pancreatic cancer	0.00163	0.00168	CcSEcCtD
Methyldopa—Leukopenia—Docetaxel—pancreatic cancer	0.00162	0.00168	CcSEcCtD
Methyldopa—Body temperature increased—Fluorouracil—pancreatic cancer	0.00162	0.00167	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—pancreatic cancer	0.00161	0.00166	CcSEcCtD
Methyldopa—Weight increased—Epirubicin—pancreatic cancer	0.0016	0.00165	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—pancreatic cancer	0.00159	0.00164	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—pancreatic cancer	0.00158	0.00163	CcSEcCtD
Methyldopa—Hypersensitivity—Irinotecan—pancreatic cancer	0.00158	0.00163	CcSEcCtD
Methyldopa—Infestation—Epirubicin—pancreatic cancer	0.00156	0.00162	CcSEcCtD
Methyldopa—Infestation NOS—Epirubicin—pancreatic cancer	0.00156	0.00162	CcSEcCtD
Methyldopa—Arthralgia—Docetaxel—pancreatic cancer	0.00154	0.00159	CcSEcCtD
Methyldopa—Myalgia—Docetaxel—pancreatic cancer	0.00154	0.00159	CcSEcCtD
Methyldopa—Nausea—Sunitinib—pancreatic cancer	0.00154	0.00159	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—pancreatic cancer	0.00154	0.00159	CcSEcCtD
Methyldopa—Asthenia—Irinotecan—pancreatic cancer	0.00153	0.00159	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00153	0.00158	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—pancreatic cancer	0.00152	0.00158	CcSEcCtD
Methyldopa—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00151	0.00156	CcSEcCtD
Methyldopa—Asthenia—Gemcitabine—pancreatic cancer	0.0015	0.00155	CcSEcCtD
Methyldopa—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.00148	0.00153	CcSEcCtD
Methyldopa—Oedema—Docetaxel—pancreatic cancer	0.00148	0.00153	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—pancreatic cancer	0.00148	0.00153	CcSEcCtD
Methyldopa—Infection—Docetaxel—pancreatic cancer	0.00147	0.00152	CcSEcCtD
Methyldopa—Diarrhoea—Irinotecan—pancreatic cancer	0.00146	0.00151	CcSEcCtD
Methyldopa—Agranulocytosis—Epirubicin—pancreatic cancer	0.00146	0.00151	CcSEcCtD
Methyldopa—Nervous system disorder—Docetaxel—pancreatic cancer	0.00145	0.0015	CcSEcCtD
Methyldopa—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00145	0.0015	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—pancreatic cancer	0.00145	0.0015	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—pancreatic cancer	0.00145	0.0015	CcSEcCtD
Methyldopa—Skin disorder—Docetaxel—pancreatic cancer	0.00144	0.00148	CcSEcCtD
Methyldopa—Bradycardia—Epirubicin—pancreatic cancer	0.00143	0.00148	CcSEcCtD
Methyldopa—Diarrhoea—Gemcitabine—pancreatic cancer	0.00143	0.00147	CcSEcCtD
Methyldopa—Dizziness—Irinotecan—pancreatic cancer	0.00141	0.00146	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—pancreatic cancer	0.00141	0.00146	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—pancreatic cancer	0.0014	0.00145	CcSEcCtD
Methyldopa—Diarrhoea—Fluorouracil—pancreatic cancer	0.0014	0.00145	CcSEcCtD
Methyldopa—Connective tissue disorder—Epirubicin—pancreatic cancer	0.00138	0.00143	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00137	0.00141	CcSEcCtD
Methyldopa—Vomiting—Irinotecan—pancreatic cancer	0.00136	0.00141	CcSEcCtD
Methyldopa—Dizziness—Fluorouracil—pancreatic cancer	0.00135	0.0014	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—pancreatic cancer	0.00135	0.0014	CcSEcCtD
Methyldopa—Rash—Irinotecan—pancreatic cancer	0.00135	0.00139	CcSEcCtD
Methyldopa—Dermatitis—Irinotecan—pancreatic cancer	0.00135	0.00139	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00135	0.00139	CcSEcCtD
Methyldopa—Headache—Irinotecan—pancreatic cancer	0.00134	0.00138	CcSEcCtD
Methyldopa—Paraesthesia—Docetaxel—pancreatic cancer	0.00133	0.00137	CcSEcCtD
Methyldopa—Vomiting—Gemcitabine—pancreatic cancer	0.00132	0.00137	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—pancreatic cancer	0.00132	0.00137	CcSEcCtD
Methyldopa—Rash—Gemcitabine—pancreatic cancer	0.00131	0.00136	CcSEcCtD
Methyldopa—Dermatitis—Gemcitabine—pancreatic cancer	0.00131	0.00136	CcSEcCtD
Methyldopa—Headache—Gemcitabine—pancreatic cancer	0.00131	0.00135	CcSEcCtD
Methyldopa—Cardiac disorder—Epirubicin—pancreatic cancer	0.0013	0.00135	CcSEcCtD
Methyldopa—Vomiting—Fluorouracil—pancreatic cancer	0.0013	0.00135	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—pancreatic cancer	0.0013	0.00134	CcSEcCtD
Methyldopa—Rash—Fluorouracil—pancreatic cancer	0.00129	0.00134	CcSEcCtD
Methyldopa—Dermatitis—Fluorouracil—pancreatic cancer	0.00129	0.00133	CcSEcCtD
Methyldopa—Headache—Fluorouracil—pancreatic cancer	0.00128	0.00133	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00128	0.00132	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.00128	0.00132	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—pancreatic cancer	0.00127	0.00132	CcSEcCtD
Methyldopa—Nausea—Irinotecan—pancreatic cancer	0.00127	0.00131	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—pancreatic cancer	0.00127	0.00131	CcSEcCtD
Methyldopa—Constipation—Docetaxel—pancreatic cancer	0.00126	0.00131	CcSEcCtD
Methyldopa—Nausea—Gemcitabine—pancreatic cancer	0.00124	0.00128	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—pancreatic cancer	0.00123	0.00127	CcSEcCtD
Methyldopa—Nausea—Fluorouracil—pancreatic cancer	0.00122	0.00126	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—pancreatic cancer	0.00121	0.00125	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—pancreatic cancer	0.0012	0.00124	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—pancreatic cancer	0.00118	0.00122	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.00117	0.00121	CcSEcCtD
Methyldopa—Body temperature increased—Docetaxel—pancreatic cancer	0.00117	0.00121	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—pancreatic cancer	0.00114	0.00118	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—pancreatic cancer	0.00111	0.00115	CcSEcCtD
Methyldopa—Leukopenia—Epirubicin—pancreatic cancer	0.00109	0.00113	CcSEcCtD
Methyldopa—Hypersensitivity—Docetaxel—pancreatic cancer	0.00109	0.00113	CcSEcCtD
Methyldopa—Asthenia—Docetaxel—pancreatic cancer	0.00106	0.0011	CcSEcCtD
Methyldopa—Myalgia—Epirubicin—pancreatic cancer	0.00104	0.00108	CcSEcCtD
Methyldopa—Arthralgia—Epirubicin—pancreatic cancer	0.00104	0.00108	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00103	0.00107	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—pancreatic cancer	0.00101	0.00105	CcSEcCtD
Methyldopa—Diarrhoea—Docetaxel—pancreatic cancer	0.00101	0.00105	CcSEcCtD
Methyldopa—Oedema—Epirubicin—pancreatic cancer	0.000997	0.00103	CcSEcCtD
Methyldopa—Infection—Epirubicin—pancreatic cancer	0.000991	0.00102	CcSEcCtD
Methyldopa—Nervous system disorder—Epirubicin—pancreatic cancer	0.000978	0.00101	CcSEcCtD
Methyldopa—Dizziness—Docetaxel—pancreatic cancer	0.000978	0.00101	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000977	0.00101	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—pancreatic cancer	0.000969	0.001	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—pancreatic cancer	0.000963	0.000995	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—pancreatic cancer	0.000963	0.000995	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000956	0.000988	CcSEcCtD
Methyldopa—Vomiting—Docetaxel—pancreatic cancer	0.00094	0.000972	CcSEcCtD
Methyldopa—Rash—Docetaxel—pancreatic cancer	0.000932	0.000964	CcSEcCtD
Methyldopa—Dermatitis—Docetaxel—pancreatic cancer	0.000932	0.000963	CcSEcCtD
Methyldopa—Headache—Docetaxel—pancreatic cancer	0.000926	0.000957	CcSEcCtD
Methyldopa—Oedema—Doxorubicin—pancreatic cancer	0.000923	0.000954	CcSEcCtD
Methyldopa—Infection—Doxorubicin—pancreatic cancer	0.000917	0.000948	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000909	0.000939	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000905	0.000935	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000904	0.000934	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—pancreatic cancer	0.000896	0.000926	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—pancreatic cancer	0.000896	0.000926	CcSEcCtD
Methyldopa—Nausea—Docetaxel—pancreatic cancer	0.000878	0.000908	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000861	0.00089	CcSEcCtD
Methyldopa—Constipation—Epirubicin—pancreatic cancer	0.000853	0.000882	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000841	0.000869	CcSEcCtD
Methyldopa—Paraesthesia—Doxorubicin—pancreatic cancer	0.000829	0.000856	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000797	0.000823	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—pancreatic cancer	0.000789	0.000816	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—pancreatic cancer	0.000789	0.000815	CcSEcCtD
Methyldopa—Hypersensitivity—Epirubicin—pancreatic cancer	0.000735	0.000759	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—pancreatic cancer	0.00073	0.000754	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—pancreatic cancer	0.000716	0.00074	CcSEcCtD
Methyldopa—Diarrhoea—Epirubicin—pancreatic cancer	0.000682	0.000705	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00068	0.000703	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—pancreatic cancer	0.000662	0.000684	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—pancreatic cancer	0.00066	0.000682	CcSEcCtD
Methyldopa—Vomiting—Epirubicin—pancreatic cancer	0.000634	0.000655	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—pancreatic cancer	0.000631	0.000653	CcSEcCtD
Methyldopa—Rash—Epirubicin—pancreatic cancer	0.000629	0.00065	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—pancreatic cancer	0.000628	0.000649	CcSEcCtD
Methyldopa—Headache—Epirubicin—pancreatic cancer	0.000625	0.000646	CcSEcCtD
Methyldopa—Dizziness—Doxorubicin—pancreatic cancer	0.00061	0.000631	CcSEcCtD
Methyldopa—Nausea—Epirubicin—pancreatic cancer	0.000592	0.000612	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—pancreatic cancer	0.000587	0.000606	CcSEcCtD
Methyldopa—Rash—Doxorubicin—pancreatic cancer	0.000582	0.000601	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—pancreatic cancer	0.000581	0.000601	CcSEcCtD
Methyldopa—Headache—Doxorubicin—pancreatic cancer	0.000578	0.000598	CcSEcCtD
Methyldopa—Nausea—Doxorubicin—pancreatic cancer	0.000548	0.000567	CcSEcCtD
Methyldopa—ADRA2A—GPCR ligand binding—PRLHR—pancreatic cancer	8.82e-05	0.00518	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	8.78e-05	0.00516	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PRSS1—pancreatic cancer	8.52e-05	0.005	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CNR2—pancreatic cancer	8.37e-05	0.00491	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—VEGFA—pancreatic cancer	8.1e-05	0.00476	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	7.77e-05	0.00456	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	7.64e-05	0.00449	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PRSS1—pancreatic cancer	7.57e-05	0.00444	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SSTR3—pancreatic cancer	7.5e-05	0.00441	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	7.49e-05	0.0044	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ARG2—pancreatic cancer	7.39e-05	0.00434	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—PTEN—pancreatic cancer	7.32e-05	0.0043	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SSTR1—pancreatic cancer	7.19e-05	0.00422	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PPY—pancreatic cancer	7.05e-05	0.00414	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—TNF—pancreatic cancer	6.94e-05	0.00408	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SSTR2—pancreatic cancer	6.92e-05	0.00407	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	6.83e-05	0.00401	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCKBR—pancreatic cancer	6.69e-05	0.00393	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	6.66e-05	0.00391	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ARG2—pancreatic cancer	6.56e-05	0.00385	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	6.55e-05	0.00384	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—SST—pancreatic cancer	6.51e-05	0.00382	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TYMP—pancreatic cancer	6.46e-05	0.00379	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CNR1—pancreatic cancer	6.01e-05	0.00353	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA5—pancreatic cancer	5.79e-05	0.0034	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—AKT1—pancreatic cancer	5.77e-05	0.00339	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TYMP—pancreatic cancer	5.74e-05	0.00337	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	5.58e-05	0.00327	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PPP2R5B—pancreatic cancer	5.47e-05	0.00321	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SCT—pancreatic cancer	5.45e-05	0.0032	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GLP1R—pancreatic cancer	5.21e-05	0.00306	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCK—pancreatic cancer	5.2e-05	0.00305	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	5.18e-05	0.00304	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	5.14e-05	0.00302	CbGpPWpGaD
Methyldopa—DDC—Metabolism—DPYD—pancreatic cancer	5.12e-05	0.00301	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CNR2—pancreatic cancer	5.07e-05	0.00298	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—GLP1R—pancreatic cancer	5.07e-05	0.00298	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—pancreatic cancer	5e-05	0.00293	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCKAR—pancreatic cancer	4.99e-05	0.00293	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC2A2—pancreatic cancer	4.86e-05	0.00285	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	4.78e-05	0.0028	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GLP1R—pancreatic cancer	4.62e-05	0.00271	CbGpPWpGaD
Methyldopa—COMT—Metabolism—DPYD—pancreatic cancer	4.55e-05	0.00267	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SHH—pancreatic cancer	4.55e-05	0.00267	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRLHR—pancreatic cancer	4.53e-05	0.00266	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—IAPP—pancreatic cancer	4.49e-05	0.00264	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	4.4e-05	0.00258	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC2A2—pancreatic cancer	4.32e-05	0.00253	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTHLH—pancreatic cancer	4.31e-05	0.00253	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTCH1—pancreatic cancer	4.31e-05	0.00253	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—HRAS—pancreatic cancer	4.26e-05	0.0025	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—SSTR3—pancreatic cancer	4.24e-05	0.00249	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GDI2—pancreatic cancer	4.15e-05	0.00244	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GDI1—pancreatic cancer	4.15e-05	0.00244	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—SSTR1—pancreatic cancer	4.07e-05	0.00239	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PPY—pancreatic cancer	3.99e-05	0.00234	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SST—pancreatic cancer	3.94e-05	0.00231	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—SSTR2—pancreatic cancer	3.91e-05	0.0023	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SSTR3—pancreatic cancer	3.85e-05	0.00226	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCKBR—pancreatic cancer	3.78e-05	0.00222	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CD44—pancreatic cancer	3.76e-05	0.00221	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SSTR1—pancreatic cancer	3.69e-05	0.00217	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CNR1—pancreatic cancer	3.64e-05	0.00214	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PPY—pancreatic cancer	3.62e-05	0.00213	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	3.62e-05	0.00212	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GCG—pancreatic cancer	3.61e-05	0.00212	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	3.58e-05	0.0021	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SSTR2—pancreatic cancer	3.55e-05	0.00209	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—GCG—pancreatic cancer	3.51e-05	0.00206	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCKBR—pancreatic cancer	3.43e-05	0.00202	CbGpPWpGaD
Methyldopa—DDC—Metabolism—STK11—pancreatic cancer	3.39e-05	0.00199	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—AGTR1—pancreatic cancer	3.35e-05	0.00197	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CD44—pancreatic cancer	3.34e-05	0.00196	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CD44—pancreatic cancer	3.28e-05	0.00192	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—HRAS—pancreatic cancer	3.26e-05	0.00192	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GAST—pancreatic cancer	3.25e-05	0.00191	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GCG—pancreatic cancer	3.2e-05	0.00188	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	3.18e-05	0.00187	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA1—pancreatic cancer	3.17e-05	0.00186	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—SCT—pancreatic cancer	3.08e-05	0.00181	CbGpPWpGaD
Methyldopa—COMT—Metabolism—STK11—pancreatic cancer	3.01e-05	0.00177	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PRSS1—pancreatic cancer	3.01e-05	0.00177	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA2—pancreatic cancer	2.95e-05	0.00173	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GAST—pancreatic cancer	2.95e-05	0.00173	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCK—pancreatic cancer	2.94e-05	0.00173	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TYMS—pancreatic cancer	2.92e-05	0.00171	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CNR2—pancreatic cancer	2.86e-05	0.00168	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GLP1R—pancreatic cancer	2.86e-05	0.00168	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCKAR—pancreatic cancer	2.82e-05	0.00165	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SCT—pancreatic cancer	2.8e-05	0.00164	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	2.77e-05	0.00163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRLHR—pancreatic cancer	2.68e-05	0.00157	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCK—pancreatic cancer	2.67e-05	0.00157	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ARG2—pancreatic cancer	2.61e-05	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GLP1R—pancreatic cancer	2.6e-05	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CNR2—pancreatic cancer	2.6e-05	0.00153	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TYMS—pancreatic cancer	2.59e-05	0.00152	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCKAR—pancreatic cancer	2.56e-05	0.0015	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IAPP—pancreatic cancer	2.54e-05	0.00149	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—pancreatic cancer	2.54e-05	0.00149	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ACVR1B—pancreatic cancer	2.52e-05	0.00148	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ZNRF3—pancreatic cancer	2.52e-05	0.00148	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PTHLH—pancreatic cancer	2.44e-05	0.00143	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOE—pancreatic cancer	2.37e-05	0.00139	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SHH—pancreatic cancer	2.33e-05	0.00137	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IAPP—pancreatic cancer	2.3e-05	0.00135	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMP—pancreatic cancer	2.28e-05	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR3—pancreatic cancer	2.27e-05	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DTX1—pancreatic cancer	2.27e-05	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—SST—pancreatic cancer	2.23e-05	0.00131	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	2.22e-05	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTHLH—pancreatic cancer	2.21e-05	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTCH1—pancreatic cancer	2.21e-05	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR1—pancreatic cancer	2.18e-05	0.00128	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	2.16e-05	0.00127	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—pancreatic cancer	2.14e-05	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPY—pancreatic cancer	2.14e-05	0.00126	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOE—pancreatic cancer	2.11e-05	0.00124	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR2—pancreatic cancer	2.1e-05	0.00123	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAU—pancreatic cancer	2.1e-05	0.00123	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARG—pancreatic cancer	2.07e-05	0.00121	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CNR1—pancreatic cancer	2.06e-05	0.00121	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCKBR—pancreatic cancer	2.03e-05	0.00119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SST—pancreatic cancer	2.02e-05	0.00119	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	2.02e-05	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	1.99e-05	0.00117	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GCG—pancreatic cancer	1.99e-05	0.00117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLI1—pancreatic cancer	1.91e-05	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DTX4—pancreatic cancer	1.91e-05	0.00112	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—pancreatic cancer	1.9e-05	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGTR1—pancreatic cancer	1.89e-05	0.00111	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—pancreatic cancer	1.88e-05	0.00111	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CNR1—pancreatic cancer	1.87e-05	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—pancreatic cancer	1.86e-05	0.00109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRP1—pancreatic cancer	1.85e-05	0.00109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP2R5B—pancreatic cancer	1.85e-05	0.00109	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EGF—pancreatic cancer	1.84e-05	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GLP1R—pancreatic cancer	1.84e-05	0.00108	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—pancreatic cancer	1.84e-05	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—DPYD—pancreatic cancer	1.81e-05	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GCG—pancreatic cancer	1.8e-05	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HEY2—pancreatic cancer	1.78e-05	0.00105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GAST—pancreatic cancer	1.74e-05	0.00102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGTR1—pancreatic cancer	1.72e-05	0.00101	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A2—pancreatic cancer	1.72e-05	0.00101	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	1.69e-05	0.000992	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—pancreatic cancer	1.67e-05	0.000982	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SCT—pancreatic cancer	1.65e-05	0.00097	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HEY1—pancreatic cancer	1.65e-05	0.00097	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—pancreatic cancer	1.64e-05	0.000964	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—pancreatic cancer	1.64e-05	0.000962	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—pancreatic cancer	1.63e-05	0.000955	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCK—pancreatic cancer	1.58e-05	0.000926	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR2—pancreatic cancer	1.54e-05	0.000902	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLP1R—pancreatic cancer	1.54e-05	0.000902	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—pancreatic cancer	1.54e-05	0.000902	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCKAR—pancreatic cancer	1.51e-05	0.000887	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAG2—pancreatic cancer	1.47e-05	0.000861	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—pancreatic cancer	1.46e-05	0.000856	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MEN1—pancreatic cancer	1.44e-05	0.000848	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—pancreatic cancer	1.44e-05	0.000848	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—pancreatic cancer	1.43e-05	0.000839	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—pancreatic cancer	1.42e-05	0.000833	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	1.38e-05	0.000811	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SHH—pancreatic cancer	1.38e-05	0.000809	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH4—pancreatic cancer	1.37e-05	0.000804	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IAPP—pancreatic cancer	1.36e-05	0.000799	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD44—pancreatic cancer	1.33e-05	0.00078	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTHLH—pancreatic cancer	1.31e-05	0.000767	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTCH1—pancreatic cancer	1.31e-05	0.000767	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCG—pancreatic cancer	1.27e-05	0.000748	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—pancreatic cancer	1.26e-05	0.00074	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—STK11—pancreatic cancer	1.2e-05	0.000703	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SST—pancreatic cancer	1.19e-05	0.000702	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—pancreatic cancer	1.18e-05	0.000692	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAG1—pancreatic cancer	1.17e-05	0.000687	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH3—pancreatic cancer	1.16e-05	0.000684	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—pancreatic cancer	1.15e-05	0.000672	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—pancreatic cancer	1.12e-05	0.000655	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR1—pancreatic cancer	1.1e-05	0.000647	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NRAS—pancreatic cancer	1.1e-05	0.000647	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—pancreatic cancer	1.07e-05	0.000628	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GCG—pancreatic cancer	1.07e-05	0.000625	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.04e-05	0.000608	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMS—pancreatic cancer	1.03e-05	0.000605	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—pancreatic cancer	1.02e-05	0.000601	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR1—pancreatic cancer	1.02e-05	0.000597	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STK11—pancreatic cancer	1e-05	0.000588	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—pancreatic cancer	1e-05	0.000588	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—pancreatic cancer	9.48e-06	0.000557	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—pancreatic cancer	9.41e-06	0.000552	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	9.03e-06	0.00053	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—pancreatic cancer	8.89e-06	0.000522	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	8.77e-06	0.000515	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	8.71e-06	0.000511	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	8.68e-06	0.000509	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	8.56e-06	0.000503	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—pancreatic cancer	8.43e-06	0.000495	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—pancreatic cancer	8.38e-06	0.000492	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	8.2e-06	0.000481	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—pancreatic cancer	8.18e-06	0.00048	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—pancreatic cancer	8.06e-06	0.000473	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	7.88e-06	0.000463	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	7.56e-06	0.000444	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	7.5e-06	0.000441	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—pancreatic cancer	7.3e-06	0.000428	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—pancreatic cancer	7.26e-06	0.000426	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	7.18e-06	0.000421	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	7.16e-06	0.00042	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—pancreatic cancer	7.12e-06	0.000418	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	7.01e-06	0.000411	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	6.86e-06	0.000403	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	6.65e-06	0.00039	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	6.53e-06	0.000383	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	6.46e-06	0.00038	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	6.32e-06	0.000371	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	6.32e-06	0.000371	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	6.25e-06	0.000367	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	5.79e-06	0.00034	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	5.76e-06	0.000338	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—pancreatic cancer	5.74e-06	0.000337	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	5.56e-06	0.000326	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.51e-06	0.000323	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	5.44e-06	0.000319	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—pancreatic cancer	5.01e-06	0.000294	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	5e-06	0.000294	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	4.84e-06	0.000284	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	4.66e-06	0.000273	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	4.63e-06	0.000272	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.5e-06	0.000264	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	4.46e-06	0.000262	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	4.34e-06	0.000255	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	4.29e-06	0.000252	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	4.21e-06	0.000247	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	4.19e-06	0.000246	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	4.08e-06	0.00024	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	3.88e-06	0.000228	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	3.78e-06	0.000222	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	3.74e-06	0.00022	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	3.73e-06	0.000219	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	3.53e-06	0.000207	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	3.48e-06	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	3.47e-06	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	3.4e-06	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	3.21e-06	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.95e-06	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—pancreatic cancer	2.89e-06	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	2.86e-06	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	2.73e-06	0.00016	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.41e-06	0.000142	CbGpPWpGaD
